These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 9533776)

  • 21. Sulfonylbenzoyl-nitrostyrenes: potential bisubstrate type inhibitors of the EGF-receptor tyrosine protein kinase.
    Traxler PM; Wacker O; Bach HL; Geissler JF; Kump W; Meyer T; Regenass U; Roesel JL; Lydon N
    J Med Chem; 1991 Aug; 34(8):2328-37. PubMed ID: 1652014
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapy of human transitional cell carcinoma of the bladder by oral administration of the epidermal growth factor receptor protein tyrosine kinase inhibitor 4,5-dianilinophthalimide.
    Dinney CP; Parker C; Dong Z; Fan D; Eve BY; Bucana C; Radinsky R
    Clin Cancer Res; 1997 Feb; 3(2):161-8. PubMed ID: 9815668
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies.
    Baselga J; Norton L; Masui H; Pandiella A; Coplan K; Miller WH; Mendelsohn J
    J Natl Cancer Inst; 1993 Aug; 85(16):1327-33. PubMed ID: 8340945
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro pharmacological characterization of PD 166285, a new nanomolar potent and broadly active protein tyrosine kinase inhibitor.
    Panek RL; Lu GH; Klutchko SR; Batley BL; Dahring TK; Hamby JM; Hallak H; Doherty AM; Keiser JA
    J Pharmacol Exp Ther; 1997 Dec; 283(3):1433-44. PubMed ID: 9400019
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The anti-proliferative effects of tyrosine kinase inhibitors towards tamoxifen-sensitive and tamoxifen-resistant human breast cancer cell lines in relation to the expression of epidermal growth factor receptors (EGF-R) and the inhibition of EGF-R tyrosine kinase.
    El-Zarruk AA; van den Berg HW
    Cancer Lett; 1999 Aug; 142(2):185-93. PubMed ID: 10463775
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy.
    Bleeker WK; Lammerts van Bueren JJ; van Ojik HH; Gerritsen AF; Pluyter M; Houtkamp M; Halk E; Goldstein J; Schuurman J; van Dijk MA; van de Winkel JG; Parren PW
    J Immunol; 2004 Oct; 173(7):4699-707. PubMed ID: 15383606
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Blockade of epidermal growth factor receptor signaling leads to inhibition of renal cell carcinoma growth in the bone of nude mice.
    Weber KL; Doucet M; Price JE; Baker C; Kim SJ; Fidler IJ
    Cancer Res; 2003 Jun; 63(11):2940-7. PubMed ID: 12782601
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of the epidermal growth factor receptor tyrosine kinase by PD153035 in human A431 tumors in athymic nude mice.
    Kunkel MW; Hook KE; Howard CT; Przybranowski S; Roberts BJ; Elliott WL; Leopold WR
    Invest New Drugs; 1996; 13(4):295-302. PubMed ID: 8824347
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.
    Mendel DB; Laird AD; Xin X; Louie SG; Christensen JG; Li G; Schreck RE; Abrams TJ; Ngai TJ; Lee LB; Murray LJ; Carver J; Chan E; Moss KG; Haznedar JO; Sukbuntherng J; Blake RA; Sun L; Tang C; Miller T; Shirazian S; McMahon G; Cherrington JM
    Clin Cancer Res; 2003 Jan; 9(1):327-37. PubMed ID: 12538485
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148).
    Beran M; Cao X; Estrov Z; Jeha S; Jin G; O'Brien S; Talpaz M; Arlinghaus RB; Lydon NB; Kantarjian H
    Clin Cancer Res; 1998 Jul; 4(7):1661-72. PubMed ID: 9676840
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antitumor activity of the selective epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) Iressa (ZD1839) in an EGFR-expressing multidrug-resistant cell line in vitro and in vivo.
    Naruse I; Ohmori T; Ao Y; Fukumoto H; Kuroki T; Mori M; Saijo N; Nishio K
    Int J Cancer; 2002 Mar; 98(2):310-5. PubMed ID: 11857424
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors.
    Kraker AJ; Hartl BG; Amar AM; Barvian MR; Showalter HD; Moore CW
    Biochem Pharmacol; 2000 Oct; 60(7):885-98. PubMed ID: 10974196
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Blockade of epidermal growth factor receptor signaling in tumor cells and tumor-associated endothelial cells for therapy of androgen-independent human prostate cancer growing in the bone of nude mice.
    Kim SJ; Uehara H; Karashima T; Shepherd DL; Killion JJ; Fidler IJ
    Clin Cancer Res; 2003 Mar; 9(3):1200-10. PubMed ID: 12631626
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epidermal growth factor receptor signaling cascade as target for tyrphostin (RG 50864) in epithelial cells. Paradoxical effects on mitogen-activated protein kinase kinase and mitogen-activated protein kinase activities.
    Nowak F; Jacquemin-Sablon A; Pierre J
    Biochem Pharmacol; 1997 Feb; 53(3):287-98. PubMed ID: 9065732
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transactivation of the epidermal growth factor receptor in endothelin-1-induced mitogenic signaling in human ovarian carcinoma cells.
    Vacca F; Bagnato A; Catt KJ; Tecce R
    Cancer Res; 2000 Sep; 60(18):5310-7. PubMed ID: 11016663
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mechanisms of action in NIH-3T3 cells of genistein, an inhibitor of EGF receptor tyrosine kinase activity.
    Linassier C; Pierre M; Le Pecq JB; Pierre J
    Biochem Pharmacol; 1990 Jan; 39(1):187-93. PubMed ID: 2153378
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of luteolin and quercetin, inhibitors of tyrosine kinase, on cell growth and metastasis-associated properties in A431 cells overexpressing epidermal growth factor receptor.
    Huang YT; Hwang JJ; Lee PP; Ke FC; Huang JH; Huang CJ; Kandaswami C; Middleton E; Lee MT
    Br J Pharmacol; 1999 Nov; 128(5):999-1010. PubMed ID: 10556937
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A derivative of staurosporine (CGP 41 251) shows selectivity for protein kinase C inhibition and in vitro anti-proliferative as well as in vivo anti-tumor activity.
    Meyer T; Regenass U; Fabbro D; Alteri E; Rösel J; Müller M; Caravatti G; Matter A
    Int J Cancer; 1989 May; 43(5):851-6. PubMed ID: 2714889
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [(Alkylamino)methyl]acrylophenones: potent and selective inhibitors of the epidermal growth factor receptor protein tyrosine kinase.
    Traxler P; Trinks U; Buchdunger E; Mett H; Meyer T; Müller M; Regenass U; Rösel J; Lydon N
    J Med Chem; 1995 Jun; 38(13):2441-8. PubMed ID: 7608909
    [TBL] [Abstract][Full Text] [Related]  

  • 40. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
    Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
    Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.